College of Nursing Faculty Wins AANA 2017 Researcher of the Year Award
Beth Ann Clayton, assistant professor of clinical nursing at the University of Cincinnati (UC) College of Nursing, and director of the Nurse Anesthesia program, has been awarded the 2017 Researcher of the Year by the American Association of Nurse Anesthetists (AANA).
The award was given to the AANA Foundation Closed Claims Research Team, of which Clayton is a part, for making a significant contribution to the practice of anesthesia through clinical research and for incorporating research into her professional career. In comments about the award, the AANA Foundation wrote, "The Closed Claims Research Team has enhanced the closed claims research by conducting rigorous qualitative analysis to enrich the research findings. Since its inception in 1995, the team has produced over 100 presentations, 25 posters and 10 published articles addressing anesthesia adverse outcomes.
Based on this work, Clayton was selected to review the draft document Analgesic and Anesthesia Care for the Obstetric Patient, Practice Guidelines, which is up for comments and should be implemented in late October. This document will guide anesthesia professionals who provide obstetric analgesic and anesthesia care.
Tags
Related Stories
Selecting noninvasive tests for liver disease diagnosis, monitoring
September 3, 2026
Noninvasive tests have emerged as valuable alternatives for diagnosing, staging and monitoring MASLD and MASH, according to a recent MedCentral report.
Why can it get so hot at times?
September 3, 2026
Cincinnati is experiencing more days of extreme heat this summer than in previous decades, due in large part to warmer global temperatures. But explanations for these higher temperatures also relate to regional factors, including the city's location in a river valley and large proportion of built environment.
Cancer Center plays key role in lab research, clinical trials for new pancreatic cancer drug
September 1, 2026
WLWT and WCPO highlighted the contributions of University of Cincinnati Cancer Center researchers that helped lead to the recent FDA approval of daraxonrasib, a new treatment for pancreatic cancer.